United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin phosphate 10 mg in 1 g - clindamycin and benzoyl peroxide topical gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide topical gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

european regulatory affairs t/a ivowen - clindamycin phosphate; benzoyl peroxide, hydrous - gel - 10 + 50 milligram(s)/gram - clindamycin, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - clindamycin phosphate; benzoyl peroxide, hydrous - gel - clindamycin, combinations

United States - English - NLM (National Library of Medicine)

bausch health us, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin 10 mg in 1 g - acanya® gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. acanya gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with acanya gel [see postmarketing experience (6.2)] . acanya gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see warnings and precautions (5.1)] . risk summary there are no available data on acanya gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. the limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes (see data) .in limited published cli

United States - English - NLM (National Library of Medicine)

bausch health us, llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin 10 mg in 1 g - onexton® (clindamycin phosphate and benzoyl peroxide) gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. onexton gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with onexton gel [see postmarketing experience (6.2) ]. onexton gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see warnings and precautions (5.1) ]. risk summary there are no available data on onexton gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. the limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of

Canada - English - Health Canada

taro pharmaceuticals inc - benzoyl peroxide; clindamycin (clindamycin phosphate) - gel - 5%; 1% - benzoyl peroxide 5%; clindamycin (clindamycin phosphate) 1% - antibiotics

United States - English - NLM (National Library of Medicine)

bausch health us llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin 10 mg in 1 g - benzaclin topical gel is indicated for the topical treatment of acne vulgaris. benzaclin topical gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - clindamycin (unii: 3u02el437c) (clindamycin - unii:3u02el437c) - clindamycin and benzoyl peroxide gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - clindamycin (unii: 3u02el437c) (clindamycin - unii:3u02el437c) - clindamycin and benzoyl peroxide gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - clindamycin (unii: 3u02el437c) (clindamycin - unii:3u02el437c) - clindamycin and benzoyl peroxide gel, 1%/5% is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel, 1%/5% is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.